These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18986702)

  • 1. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia.
    Rasheed W; Flaim B; Seymour JF
    Leuk Res; 2009 Jun; 33(6):861-4. PubMed ID: 18986702
    [No Abstract]   [Full Text] [Related]  

  • 2. Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography.
    Wang HC; Lee CS; Liu TC
    Kaohsiung J Med Sci; 2015 Mar; 31(3):165-6. PubMed ID: 25744241
    [No Abstract]   [Full Text] [Related]  

  • 3. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
    Orlandi EM; Rocca B; Pazzano AS; Ghio S
    Leuk Res; 2012 Jan; 36(1):e4-6. PubMed ID: 21890201
    [No Abstract]   [Full Text] [Related]  

  • 4. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
    Dumitrescu D; Seck C; ten Freyhaus H; Gerhardt F; Erdmann E; Rosenkranz S
    Eur Respir J; 2011 Jul; 38(1):218-20. PubMed ID: 21719499
    [No Abstract]   [Full Text] [Related]  

  • 5. Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
    Yun S; Anwer F; Vincelette ND
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24810451
    [No Abstract]   [Full Text] [Related]  

  • 6. Double-edged sword of the new cancer therapeutics.
    Force T
    Circulation; 2012 May; 125(17):2057-8. PubMed ID: 22451582
    [No Abstract]   [Full Text] [Related]  

  • 7. Reversible pre-capillary pulmonary hypertension due to dasatinib.
    Buchelli Ramirez HL; Álvarez Álvarez CM; Rodríguez Reguero JJ; García Clemente MM; Casan Clarà P
    Respir Care; 2014 May; 59(5):e77-80. PubMed ID: 24149673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Reversible pulmonary hypertension as a consequence of dasatinib treatment in a patient with chronic myeloid leukemia and scleroderma].
    Ryczek R; Góra-Tybor J; Betkier-Lipińska K; Cwetsch A
    Pol Merkur Lekarski; 2013 Jun; 34(204):342-4. PubMed ID: 23882932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reversible pulmonary arterial hypertension related to dasatinib in the treatment for chronic myelogenous leukemia: a case report and literature review].
    Liu B; Wang Y; Mi Y; Wang J
    Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):581-6. PubMed ID: 25052596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
    Sano M; Saotome M; Urushida T; Katoh H; Satoh H; Ohnishi K; Hayashi H
    Intern Med; 2012; 51(17):2337-40. PubMed ID: 22975544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib in chronic myelogenous leukemia.
    Kathula SK
    N Engl J Med; 2006 Sep; 355(10):1062; author reply 1063-4. PubMed ID: 16957155
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
    Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
    Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis.
    de Lavallade H; Punnialingam S; Milojkovic D; Bua M; Khorashad JS; Gabriel IH; Chaidos A; Olavarria E; Goldman JM; Apperley JF; Marin D
    Br J Haematol; 2008 May; 141(5):745-7. PubMed ID: 18331365
    [No Abstract]   [Full Text] [Related]  

  • 14. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
    Taçoy G; Çengel A; Özkurt ZN; Türkoğlu S
    Turk Kardiyol Dern Ars; 2015 Jan; 43(1):78-81. PubMed ID: 25655855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.
    Roux C; Nicolini FE; Rea D; Niault M; Mollica L; Berger F; Chassagne-Clément C; Tigaud I; Tulliez M; Giraudier S; Turhan A; Rousselot P; Legros L
    Blood; 2013 Oct; 122(17):3082-4. PubMed ID: 24159167
    [No Abstract]   [Full Text] [Related]  

  • 16. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].
    Edahiro Y; Takaku T; Konishi H; Tsukune Y; Fujioka I; Takasu K; Gotoh A; Daida H; Komatsu N
    Rinsho Ketsueki; 2017; 58(11):2213-2218. PubMed ID: 29212971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia.
    Hong JH; Lee SE; Choi SY; Kim SH; Jang EJ; Bang JH; Park JE; Jeon HR; Oh YJ; Yi JE; Jung HO; Youn HJ; Kim DW
    Cancer Res Treat; 2015 Oct; 47(4):937-42. PubMed ID: 25648097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Reversible dasatinib-related pulmonary arterial hypertension in a CML patient].
    Nagasaki J; Aoyama Y; Nomoto Y; Ido K; Ichihara H; Mugitani A
    Rinsho Ketsueki; 2016 May; 57(5):618-23. PubMed ID: 27263788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
    Zwaan CM; Rizzari C; Mechinaud F; Lancaster DL; Lehrnbecher T; van der Velden VH; Beverloo BB; den Boer ML; Pieters R; Reinhardt D; Dworzak M; Rosenberg J; Manos G; Agrawal S; Strauss L; Baruchel A; Kearns PR
    J Clin Oncol; 2013 Jul; 31(19):2460-8. PubMed ID: 23715577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.